http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
Epigenetic regulation in overcoming chemoresistance
"Epigenetic Regulation in Overcoming Chemoresistance, Volume 16, explains how epigenetic agents can enhance the chemotherapy sensitivity of diverse types of cancers. The book provides a comprehensive delineation and the recent development of the scientific studies on the epigenetic regulation in enhancing chemo-sensitivity. In addition, it discusses several topics such as DNA methyltransferase inhibitors (DNMTi), Histone deacetylases inhibitors (HDACi), Histone lysine demethylases inhibitors (HDMi), Histone lysine methyltransferases inhibitors (HMTi) and drugs regulating the microRNA, long non-coding RNA (lncRNA) or RNA methylation. Finally, recent and future developments of the field of epigenetic regulation are explored. This is a valuable resource for cancer researchers, clinicians, graduate students and several members of biomedical field who are interested in learning about epigenetic regulation methods to reverse chemo-resistance in cancers"--
Intro -- Epigenetic Regulation in Overcoming Chemoresistance -- Copyright -- Cover Image Insert -- Aims and Scope for Series ``Cancer Sensitizing Agents for Chemotherapy´´ -- About the Series Editor -- Aims and Scope of the Volume -- About the Volume Editors -- Preface -- Contents -- Contributors -- Chapter 1: The role of epigenetic regulation in cancer -- Introduction -- DNA methylation -- Histone modification -- RNA regulation -- Conclusion -- References -- Chapter 2: DNA methyltransferase inhibitors (DNMTis) as sensitizing agents to overcome chemoresistance -- Aberrant DNA methylation in cancer -- Deregulation of DNA methyltransferases in cancer -- DNA methyltransferase inhibitors (DNMTis) in cancer therapy -- DNMTi as sensitizing agents for chemotherapy -- Global aberrant DNA methylation induces chemoresistance -- Regional DNA hypermethylation induces chemoresistance -- Antiapoptosis proteins and proliferation-related genes -- DNA damage repair proteins -- Drug-target interactions -- PI3K/Akt pathway -- MicroRNAS -- Combination of DNMTis with other therapies -- Conclusions and prospects -- Acknowledgments -- References -- Chapter 3: Histone deacetylase inhibitors (HDACi), the ongoing epigenetic agents to enhance chemotherapy sensitization -- Introduction -- Classification and application of HDACi -- Hydroxamic acids as HDACi -- Cyclic peptides as HDACi -- Short-chain fatty acids as HDACi -- Benzamides as HDACi -- Other HDACi -- HDACi enhance chemotherapy sensitization -- HDACi enhance sensitization in nonsmall cell lung cancer -- HDACi enhances sensitization in breast cancer -- HDACi enhance sensitization in prostate cancer -- HDACi enhance sensitization in gastric cancer -- HDACi enhance sensitization in liver cancer -- HDACi enhance sensitization in multiple myeloma cells -- Summary -- References.
Chapter 4: Histone lysine demethylase inhibitor (HDMi) as chemo-sensitizing agent -- The nature of histone modifications -- The dynamics of histone methylation -- Histone lysine demethylases -- Dysregulation of KDMs in cancers -- Aberrant KDMs and chemoresistance -- KDM1/LSD inhibitors as chemo-sensitizing agents -- JmjC demethylase inhibitors as chemo-sensitizing agents -- Concluding remarks -- Acknowledgment -- References -- Chapter 5: Targeting histone lysine methyltransferases for drug sensitization -- An overview of histone methylation -- Histone lysine methyltransferases -- Dysregulation of KMTs in cancers -- Targeting EZH2 for drug sensitization -- G9a, DOT1L, and other KMTs in drug sensitization -- Conclusion and outlook -- Acknowledgments -- References -- Chapter 6: Ribonucleotide base-modifying enzymes and diseases -- Introduction -- Guanine-modification enzymes -- METTL1 -- MRM3 -- TRMT10A -- TRMT10C -- Cytosine-modification enzymes -- DNMT2 -- NAT10 -- Uridine-modification enzymes -- ALKBH8 -- PUS1 -- Adenine-modification enzymes -- TRMT61B -- METTL3 -- FTO -- ALKBH5 -- Conclusion -- Acknowledgments -- References -- Chapter 7: The combination strategy with epigenetic therapy, chemotherapy, and immunotherapy -- Introduction -- Epigenetic therapy combining with chemotherapy -- Combination of HDAC inhibitors and chemotherapy -- Combination of BET inhibitors and chemotherapy -- Combination of EZH2 inhibitors and chemotherapy -- Combination of LSD1 inhibitors and chemotherapy -- Combination of DNMT inhibitors and chemotherapy -- Epigenetic therapy combining with immunotherapy -- Combination of HDAC inhibitors and immunotherapy -- Combination of BET inhibitors and immunotherapy -- Combination of EZH2 inhibitors and immunotherapy -- Combination of LSD1 inhibitors and immunotherapy -- Conclusion and prospect -- References.
Chapter 8: Future epigenetic treatment strategies -- Introduction -- The promising epigenetic therapy -- New approaches for epigenetic therapy -- The therapies targeting ncRNA -- miRNA in chemoresistance -- Epigenetic therapies targeting miRNA -- Nanostructured carriers -- Bioactive compounds and Chinese herbal compounds -- The lncRNA in chemoresistance -- Epigenetic therapies targeting lncRNA -- Nanostructured carriers -- Bioactive compounds and Chinese herbal compounds -- The predictive biomarkers -- The dawn and shortage of predictive biomarkers -- The discovering of epigenetic biomarkers -- Combination with targeted therapy -- EGFR-TKIs -- Antiangiogenic agents -- PI3K/AKT/mTOR pathway inhibitors -- Conclusion -- References -- Index.
Cancer sensitizing agents for chemotherapy ; 15